McKesson Sells 13% Stake in Medical-Surgical Unit for $1.25B

What happened

McKesson announced that Apollo Funds will invest $1.25 billion in convertible preferred equity to acquire about a 13% minority interest in the company's Medical-Surgical Solutions (MMS) division. The deal values the MMS unit at roughly $13 billion. McKesson will maintain operating control and majority ownership of MMS and continue to consolidate its financial results for reporting purposes. The transaction is subject to regulatory approvals and customary closing conditions. McKesson first announced its intention to spin off the MMS business through an initial public offering in May 2025, with the IPO currently targeted for the second half of calendar year 2027, pending market conditions and regulatory approvals.

Why it matters

This transaction represents a significant milestone in McKesson's strategic plan to separate its MMS division and unlock value for shareholders. By bringing in Apollo as a strategic and financial partner, McKesson gains capital and expertise to support the complex carve-out process and prepare MMS for life as a standalone public company. The separation allows McKesson to focus its resources on higher-growth, higher-margin opportunities such as cancer drugs and specialty medications, which align more closely with the company's long-term enterprise strategy. The MMS division, which generated $3 billion in revenue during McKesson's fiscal third quarter (a 1% increase), has experienced sluggish growth since 2020 due to supply chain disruptions, lower volumes, and shifting post-pandemic demand. As an independent entity, MMS could operate with greater focus and flexibility while McKesson streamlines its portfolio.

Bigger picture

McKesson's move to divest MMS reflects a broader strategic shift in the healthcare distribution sector, where companies are increasingly focusing on specialized, high-margin segments rather than maintaining diverse portfolios. The MMS unit, which represented just 3.2% of McKesson's total corporate revenue at the time of the initial separation announcement, has faced headwinds in the post-pandemic environment, including lower volumes in physician office settings and reduced illness incidence. Apollo's investment provides validation of the unit's standalone potential and its critical role in healthcare supply chains outside hospital settings. McKesson has a track record of successful separations and divestitures, including its 2020 exit from Change Healthcare, which the company credits with streamlining operations and more than doubling returns on invested capital. The $13 billion valuation for MMS suggests investor confidence in the medical-surgical supply market despite recent challenges.

What to watch

Investors should monitor progress toward the planned IPO in the second half of 2027, including any updates on regulatory approvals and market conditions that could affect timing. Key indicators of MMS's readiness for independence include the completion of transition service agreements across the enterprise, which McKesson said reached a major milestone on January 1. Watch for quarterly updates on MMS revenue growth and operating profit margins, particularly whether the unit can reverse recent volume declines and improve profitability. Also track how McKesson deploys the $1.25 billion in proceeds and whether the parent company delivers on its strategy to focus on oncology and specialty pharmaceuticals. Finally, observe how Apollo's involvement influences MMS operations and whether the partnership helps accelerate the unit's growth trajectory ahead of the public listing.

This article was generated by Quantli AI using publicly available news sources.